Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis ...Middle East

-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study in China. -- An epidemiology study in China in 2010 showed that there...

Hence then, the article about gannex announces first patient dosed in phase ii clinical trial of asc42 an fxr agonist for primary biliary cholangitis was published today ( Sunday 10/04/2022 - 01:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis )

Also on site :

• ‘The Comeback’ took on Hollywood long before ‘The Studio.’ Now, Valerie Cherish will have her curtain call
• Russian air Defenses shoot down 25 Ukrainian UAVs​
• ‘Project Hail Mary’ Answers Prayers: Best Opening For MPA Movie YTD With Near $141M WW — Global B.O. Update